Therapeutic use of estrogen receptor (ER)beta-selective agonists for triggering somatotropic, organotropic and anticatabolic effects (somatotropic therapy)

摘要

This invention describes the use of estrogen receptor (ER)&bgr;-selective agonists for the production of a pharmaceutical agent for triggering somatotropic and/or organotropic effects in the CNS, the circulatory system, the skeletal system and/or the immune system in the aging male and female organism (anticatabolic therapy).